Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest update is out from Chimeric Therapeutics Ltd. ( (AU:CHM) ).
Chimeric Therapeutics Ltd. has announced the quotation of 141,250,000 fully paid ordinary securities on the ASX, effective July 25, 2025. This move is part of previously announced transactions, potentially enhancing the company’s financial flexibility and market positioning within the biotechnology sector.
More about Chimeric Therapeutics Ltd.
Chimeric Therapeutics Ltd. operates in the biotechnology industry, focusing on developing innovative therapies. The company is primarily involved in the research and development of cell therapies for cancer treatment, aiming to improve patient outcomes and expand its market presence in the oncology sector.
Technical Sentiment Signal: Sell
Current Market Cap: A$10.08M
For an in-depth examination of CHM stock, go to TipRanks’ Overview page.